Boscia senegalensis extract (BSP), a natural SGLT1/2 inhibitor, may lower blood sugar and HbA1c in type 2 diabetes
Key takeaway:
A 12-week study in 332 type 2 diabetes patients found that Boscisucrophage (BSP), a natural Boscia senegalensis seed extract, significantly lowered blood glucose and HbA1c when added to existing therapy.
Study at a glance
What was studied
Whether Boscia senegalensis extract (BSP) improves blood sugar control in T2DM
Study type
non-randomized clinical trial (non-RCT or NRCT)
duration
Short-Term (≤3 mo)
Intervention
Boscisucrophage
Outcomes
Blood glucose, HbA1c, Urine glucose excretion, Body weight
Funding
Non-industry sponsored
Main effects
↓ Blood glucose (significant reduction observed after 1 week of treatment)
↓ HbA1c (below 7% after 60 days of treatment)
↑ Urine glucose excretion via SGLT1/SGLT2 inhibition
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Boscisucrophage (Supplements) |  Blood glucose (Glycemic Control) | Decrease | Strong |
Boscisucrophage (Supplements) |  Body weight (Weight & Anthropometrics) | Decrease | Limited |
Boscisucrophage (Supplements) | HbA1c (Glycemic Control) | Decrease | Strong |
Boscisucrophage (Supplements) | Urine glucose excretion (Glycemic Control) | Increase | Strong |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- BSP significantly reduced blood glucose and HbA1c in T2DM patients resistant to oral antihyperglycemic drugs
- Increased urine glucose excretion (UGE) suggests dual SGLT1/SGLT2 inhibition mechanism
- No significant adverse effects on liver or kidney function were observed
Who this applies to
People with type 2 diabetes who have difficulty controlling blood sugar with oral medications alone, particularly in regions where Boscia senegalensis is traditionally used as a food and medicine source.
Keep in Mind
This was a preliminary single-arm study without a control group, so the results may be influenced by other factors like increased attention or natural disease changes. Randomized controlled trials are needed before firm conclusions can be drawn about BSP's effectiveness compared to standard treatments.
Between the Lines
- Single-arm uncontrolled design limits attribution of effects to BSP alone
- No randomization or blinding introduces potential bias
- BMI was not systematically recorded at baseline, limiting weight-related analysis
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Journal Reference
Eto B, Elrherabi A, Nasr FA, et al. Boscisucrophage: A Natural SGLT1/2 Inhibitor From Boscia senegalensis for Managing Type 2 Diabetes. Food Sci Nutr. 2026;14(3):e71621.
Sources
Ranked by clinical relevance and evidence quality.
Key References
Most relevant evidence and guidance related to this research.
American Diabetes Association Standards of Care in Diabetes—2025: Pharmacologic Approaches to Glycemic Treatment
Supporting Evidence
Supporting evidence and related resources.
Type 2 diabetes in adults: management
Understanding Type 2 Diabetes | ADA
What Are My Options for Type 2 Diabetes Medications? | ADA
World Health Organization - Diabetes Fact Sheet
NIH National Center for Complementary and Integrative Health - Herbal Supplements for Diabetes
Effectiveness of diet-combined exercise interventions for glycemic control in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.
13 total sources in this category
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.